The aim of the proposed three-site study is to increase the rate of full remission from major
depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both
major depressive disorder and insomnia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Stanford University
Collaborators:
Duke University University of Pennsylvania University of Pittsburgh